The predictive value of pCR in HER2-positive and TNBC was later verified by neoadjuvant trials aimed at targeted therapies and NAC and is presently the optimal level of care for stage 2 and stage 3 HER2-positive cases of breast tumors [33]. The gene discussed is ERBB2; the disease is breast neoplasm.